Natera (NTRA) to Release Earnings on Thursday

Natera (NASDAQ:NTRA) will likely be announcing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Natera to post earnings of ($0.46) per share and revenue of $600.6780 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Natera Stock Up 0.1%

NTRA opened at $209.53 on Wednesday. The firm’s 50 day moving average is $227.44 and its 200-day moving average is $203.04. The firm has a market capitalization of $28.98 billion, a P/E ratio of -91.50 and a beta of 1.64. Natera has a 52-week low of $125.38 and a 52-week high of $256.36.

Insider Activity at Natera

In related news, CFO Michael Burkes Brophy sold 6,939 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $227.83, for a total transaction of $1,580,912.37. Following the sale, the chief financial officer owned 52,120 shares of the company’s stock, valued at $11,874,499.60. The trade was a 11.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John Fesko sold 3,594 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $231.02, for a total value of $830,285.88. Following the completion of the sale, the insider owned 178,081 shares of the company’s stock, valued at $41,140,272.62. This trade represents a 1.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 368,119 shares of company stock valued at $85,956,782 over the last quarter. Corporate insiders own 5.63% of the company’s stock.

Institutional Trading of Natera

Several institutional investors have recently modified their holdings of the company. Horizon Investments LLC bought a new position in Natera during the third quarter valued at about $32,000. Bank of Jackson Hole Trust lifted its holdings in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 83 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new stake in Natera in the 4th quarter valued at about $39,000. Greenline Wealth Management LLC bought a new position in shares of Natera during the 4th quarter valued at about $41,000. Finally, HM Payson & Co. grew its stake in shares of Natera by 214.9% in the 4th quarter. HM Payson & Co. now owns 211 shares of the medical research company’s stock worth $48,000 after purchasing an additional 144 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several research analyst reports. BTIG Research raised their price objective on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. TD Cowen reissued a “buy” rating on shares of Natera in a report on Wednesday, January 7th. Wells Fargo & Company increased their price objective on shares of Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research report on Thursday, January 22nd. Finally, Morgan Stanley boosted their target price on shares of Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $249.20.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.